Raymond James analyst Christopher Raymond initiated coverage of Kalaris Therapeutics (KLRS) with a Strong Buy rating and $23 price target The stock’s current valuation reflects zero chance of the company’s lead asset TH103 showing any differentiation, let alone clinical utility when proof of concept data are presented later this year, the analyst tells investors in a research note. The firm believes TH103 has the potential to address unmet needs in the age-related macular degeneration and diabetic macular edema markets.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS:
- Kalaris Therapeutics Reports Q2 2025 Financial Results
- Kalaris Therapeutics Elects New Directors at Annual Meeting
- Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
- Kalaris Therapeutics assumed with a Neutral at Piper Sandler
- Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD